newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Company on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023 Cyclo